News & events Upcoming events Oct 16, 2025 - Oct 16, 2025 Symposium Hirngesundheit und Demenzen Bern, Switzerland More info and meet us there Oct 23, 2025 - Oct 24, 2025 Deutscher Kongress für Laboratoriumsmedizin 2025 Leipzig, Germany More info and meet us there Oct 25, 2025 - Oct 28, 2025 55° Congresso Società italiana di Neurologia Padova, Italy More info and meet us there See all upcoming events Latest news Sep 12, 2014 Fujirebio Europe releases a panel of new and established HBV assays for the LUMIPULSE® G series Fujirebio Europe today released a series of specialized assays for its chemiluminescent enzyme immunoassay (CLEIA) system, the LUMIPULSE® G1200, dedicated to the diagnosis and monitoring of HBV infection and the treatment of HBV patients. Read more Aug 13, 2014 Fujirebio Europe updates its market-leading INNO-LIA® Score strip portfolio Fujirebio Europe releases updates of its market-leading INNO-LIA® Score immunoblot product range and the associated LiRAS® for Infectious Diseases software for automated interpretation of results. The improvement of the antibody confirmation assays confirms Fujirebio Europe's strong position as one of the world leaders in strip-based diagnostics solutions. Read more Apr 28, 2014 Fujirebio Europe launches the Lumipulse® G ProGRP, a marker of choice in lung cancer management Fujirebio Europe announces the launch of its ProGRP assay to be used on the LUMIPULSE® G1200 chemiluminescent enzyme immunoassay (CLEIA) analyzer. The test is designed for the quantitative determination of ProGRP in human serum or plasma. Read more Apr 4, 2014 Fujirebio Europe streamlines its organization Fujirebio Europe today announced its intention to proceed with a reorganization in order to bring further focus and weight to the ongoing introduction of the LUMIPULSE® G1200 system on the European market, commenced in 2011. Fujirebio Europe has informed the Work’s Council in Gent about the estimated impact on employment and has communicated its intention to proceed for collective dismissal. Read more Feb 3, 2014 Fujirebio Europe confirms its engagement in neurodegeneration and updates its market-leading range of immunoassay biomarkers for Alzheimer routine testing Fujirebio Europe announces the update of its entire range of INNOTEST® biomarkers for Alzheimer testing in routine. At the same occasion the company launches the INNOTEST® β-AMYLOID (1-40) test, an immunoassay kit for the quantification of β-Amyloid(1-40) in cerebrospinal fluid. Read more Dec 11, 2013 Fujirebio Europe launches the Lumipulse® G 25-OH Vitamin D, a sensitive two-step sandwich assay Fujirebio Europe announces the launch of its novel Lumipulse® G 25-OH Vitamin D assay to be used on the LUMIPULSE® G1200 chemiluminescent enzyme immunoassay (CLEIA) analyzer. The test is designed for the quantitative determination of 25-hydroxyvitamin D in human serum or plasma to be used in the assessment of Vitamin D sufficiency. Read more Load More
Oct 16, 2025 - Oct 16, 2025 Symposium Hirngesundheit und Demenzen Bern, Switzerland More info and meet us there
Oct 23, 2025 - Oct 24, 2025 Deutscher Kongress für Laboratoriumsmedizin 2025 Leipzig, Germany More info and meet us there
Oct 25, 2025 - Oct 28, 2025 55° Congresso Società italiana di Neurologia Padova, Italy More info and meet us there
Sep 12, 2014 Fujirebio Europe releases a panel of new and established HBV assays for the LUMIPULSE® G series Fujirebio Europe today released a series of specialized assays for its chemiluminescent enzyme immunoassay (CLEIA) system, the LUMIPULSE® G1200, dedicated to the diagnosis and monitoring of HBV infection and the treatment of HBV patients. Read more
Aug 13, 2014 Fujirebio Europe updates its market-leading INNO-LIA® Score strip portfolio Fujirebio Europe releases updates of its market-leading INNO-LIA® Score immunoblot product range and the associated LiRAS® for Infectious Diseases software for automated interpretation of results. The improvement of the antibody confirmation assays confirms Fujirebio Europe's strong position as one of the world leaders in strip-based diagnostics solutions. Read more
Apr 28, 2014 Fujirebio Europe launches the Lumipulse® G ProGRP, a marker of choice in lung cancer management Fujirebio Europe announces the launch of its ProGRP assay to be used on the LUMIPULSE® G1200 chemiluminescent enzyme immunoassay (CLEIA) analyzer. The test is designed for the quantitative determination of ProGRP in human serum or plasma. Read more
Apr 4, 2014 Fujirebio Europe streamlines its organization Fujirebio Europe today announced its intention to proceed with a reorganization in order to bring further focus and weight to the ongoing introduction of the LUMIPULSE® G1200 system on the European market, commenced in 2011. Fujirebio Europe has informed the Work’s Council in Gent about the estimated impact on employment and has communicated its intention to proceed for collective dismissal. Read more
Feb 3, 2014 Fujirebio Europe confirms its engagement in neurodegeneration and updates its market-leading range of immunoassay biomarkers for Alzheimer routine testing Fujirebio Europe announces the update of its entire range of INNOTEST® biomarkers for Alzheimer testing in routine. At the same occasion the company launches the INNOTEST® β-AMYLOID (1-40) test, an immunoassay kit for the quantification of β-Amyloid(1-40) in cerebrospinal fluid. Read more
Dec 11, 2013 Fujirebio Europe launches the Lumipulse® G 25-OH Vitamin D, a sensitive two-step sandwich assay Fujirebio Europe announces the launch of its novel Lumipulse® G 25-OH Vitamin D assay to be used on the LUMIPULSE® G1200 chemiluminescent enzyme immunoassay (CLEIA) analyzer. The test is designed for the quantitative determination of 25-hydroxyvitamin D in human serum or plasma to be used in the assessment of Vitamin D sufficiency. Read more
